Detalhe da pesquisa
1.
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Gynecol Oncol
; 184: 51-56, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281412
2.
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Br J Cancer
; 128(7): 1360-1368, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690721
3.
Endocrine therapy in endometrial cancer: An old dog with new tricks.
Gynecol Oncol
; 153(1): 175-183, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30616900
4.
Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
J Oncol Pharm Pract
; 24(2): 83-90, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27856924
5.
Endometrial cancer: Not your grandmother's cancer.
Cancer
; 122(18): 2787-98, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27308732
6.
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Mod Pathol
; 29(2): 174-81, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26743472
7.
Targeting the protein kinase C family: are we there yet?
Nat Rev Cancer
; 7(7): 554-62, 2007 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17585335
8.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Carcinogenesis
; 36(9): 956-62, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26014353
9.
Intraperitoneal chemotherapy: Hot, timely, and relevant?
Cancer
; 126(24): 5206-5209, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32931026
10.
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Mod Pathol
; 28(6): 836-44, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25720322
11.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Gynecol Oncol
; 137(2): 216-22, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25769658
12.
State of the science in cervical cancer: where we are today and where we need to go.
Cancer
; 120(15): 2282-8, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24737608
13.
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Cancer
; 120(4): 603-10, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24166148
14.
Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Cancer
; 120(24): 3932-9, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25081409
15.
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Gynecol Oncol
; 134(2): 274-80, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24882554
16.
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
Gynecol Oncol
; 135(2): 184-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25173583
17.
Pan-Canadian Analysis of Practice Patterns in Small Cell Carcinoma of the Cervix: Insights from a Multidisciplinary Survey.
Curr Oncol
; 31(5): 2610-2619, 2024 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38785477
18.
Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer.
J Cancer Policy
; 36: 100421, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030536
19.
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Lancet Digit Health
; 5(2): e71-e82, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36496303
20.
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Invest New Drugs
; 30(3): 1158-63, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21400081